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Src-family kinases (SFKs) play important roles in human biology and are key drug targets as well. 
However, achieving selective inhibition of individual Src-family kinases is challenging due to the high 
similarity within the protein family. We describe rhodium(II) conjugates that deliver both potent and 
selective inhibition of Src-family SH3 domains. Rhodium(II) conjugates offer dramatic affinity 
enhancements due to interactions with specific and unique Lewis-basic histidine residues near the SH3 
binding interface, allowing predictable, structure-guided inhibition of SH3 targets that are recalcitrant to 
traditional inhibitors. In one example, a simple metallopeptide binds the Lyn SH3 domain with 6-nM affinity 
and exhibits functional activation of Lyn kinase under biologically relevant concentrations (EC50 ~200 nM).
Introduction 
 The Src-family SH3 domains are functionally important 
mediators of protein assembly and of signaling pathways that 
illustrate the problems of “undruggable” targets. SH3 domains 
are ubiquitous and versatile subunits, appearing ~300 times in 
the human genome in proteins implicated in the proliferation of 
cancer and other diseases. The domains recognize short, 
proline-rich motifs (e.g. PxxP). However, our ability to 
chemically perturb Src-family SH3 interactions in a selective 
way is limited: SH3 domain interactions are weak (Kd ~1-10 
µM) interactions at a shallow binding interface and are highly 
conserved, especially among protein families such as the Src-
family kinases. The Lyn kinase is a prototypical Src-family 
kinase. It contains a kinase domain and two regulatory 
domains: an SH3 and an SH2, which are believed to be 
involved in both upstream and downstream interactions.1,2 It 
shares significant sequence similarity with its Src-family 
brethren. Lyn and Lck, for example, have 63% sequence 
identity, similar to other comparisons within the family. 
 The SH3 domain represents an attractive and daunting 
challenge for inhibitor development. Within the Src family and 
in other related kinases, the catalytic kinase domain has been 
the primary target of inhibitor development. However, because 
the Src-family proteins have a high degree of similarity, kinase 
inhibitors can display unacceptable off-target activity. Thus the 
SH3 domain is a potentially powerful new target if truly 
selective inhibitors can be developed. In addition, SH3-
selective inhibitors would shed light on kinase biology. The 
relative roles that Lyn SH2 and SH3 interactions play in the 
plethora of upstream and downstream signaling pathways 
known for Src-family kinases are poorly understood, apart from 
limited reports.3,4 The development of domain- and protein-
specific tool compounds could untangle the roles SH3 domains 
in kinase activation, catalytic reactivity, and substrate 
preference. Efforts to inhibit SH3 interactions have met with 
limited success, both in terms of potency and selectivity. 
Peptides5,6 and peptoids7 similar to the natural target sequence 
have been used in a variety of contexts to inhibit SH3 
interactions, though IC50 ≥100 µM is typical. In one noteworthy 
approach, macromolecular, divalent ligands that bind 
simultaneously to SH3 and SH2 domains have been used to 
deliver increased potency.8,9 However, selectivity remains a 
general challenge when targeting Src-family kinases or 
members of other closely-related families.10 One small 
molecule, reported to disrupt SH3 interactions, was later shown 
to have no SH3 affinity.11-13 The Pyke group has reported 2-
aminoquinolines that bind the Tec SH3 (~10–100 µM), perhaps 
the most effective small molecule inhibitors to date.14,15 The 
HIV Nef protein binds tightly to the Hck SH3 domain, and 
exhibits half-maximal activation of Hck at 130 nM,14 though 
Nef also displays promiscuous activation of several other Src-
family kinases.16,17 
 Dirhodium conjugates have unique properties that make 
them particularly well suited as inhibitors of specific protein–
protein interactions. Dirhodium conjugates can benefit from 
metal–ligand interactions with histidine or other Lewis-basic 
residues on the surface of the target protein near the binding 
interface, offering potentially dramatic affinity benefits relative 
to traditional noncovalent organic interactions, which are 
typically weak. Dirhodium complexes are especially appealing 
in this regard due to a differential coordination environment—
containing both exchange-inert equatorial sites that allow for 
stable conjugation and also weakly-held axial ligands for 
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dynamic sampling of Lewis basic residues. Dirhodium 
complexes also have a history of biological and medical studies 
that indicating compatibility with living systems.18-23 The use of 
transition metals for such Lewis-basic anchoring of ligand 
molecules through specific interactions with the target protein 
is not widely studied. We have demonstrated inhibition with 
dirhodium cores in designed24 and natural protein25,26 contexts, 
and others have implemented similar ideas with cobalt27,28 and 
copper,29 for example. Designing metal coordination with 
protein target residues contrasts with alternative approaches 
that use transition metals as structural elements,30,31 oxidative 
damage agents,32 or cytotoxic species.33,34 
Results and discussion 
  
Figure 1. (a,b) Structures of the SH3 domains of representative Src-family 
kinases, Lyn (PDB ID: 1W1F)
35
 and Lck (PDB ID: 2IIM)
36
 with a peptide ligand (PDB 
ID: 4EIK). Histidine residues in the SH3 domain are shown explicitly. (c) 
Alignment of core SH3 residues for a variety of human Src-family (1–7) and other 
SH3 domains, highlighting histidine residues. (d) Affinity of designed rhodium(II) 
metallopeptides for three Src-family SH3 domains. 
 Sequence and structure analysis shows that Lyn has two 
non-conserved histidine residues near the top of its binding 
pocket, His78 and His96 (Figure 1a). The His96 is unique 
among Src-family sequences, and the His78 appears only in 
Hck and Lck. Individual amino-acid alterations are the only 
factors that might distinguish the nearly identical secondary 
structures and peptide-binding preferences of Src-family SH3 
domains (cf. Figure 1a, b). Based on a Src-family SH3-binding 
sequence (VSL12),37 known to binds with similar affinity 
across Src-family SH3 domains,38 we made metallopeptides 
with rhodium in different sites near the beginning of the SH3-
binding peptide. Several of these showed increased affinity 
(Figure 1). The optimal metallopeptide, S2ERh, bound to Lyn 
with 6-nM affinity. The accuracy of ITC data is reduced for C 
values >1000 (C = [protein]/Kd). Under these conditions the 
distribution of data points on the isotherm reduces the precision 
of the global fit. Since the enthalpic contributions to binding in 
the formation of the complexes described in this work were 
high, we were able to use a low protein concentration  (4 uM) 
which ensured that our C values were well below this upper 
range. (The highest C value in our work is ~670.) Isothermal 
titration calorimetry (ITC) measurements revealed an enthalpy-
driven binding event (ΔH = -13.9 kcal mol-1) with a much 
smaller entropic penalty for binding (–TΔS = 2.7 kcal mol-1) at 
25 °C. In broad terms, the thermodynamics—favourable 
enthalpy and unfavourably entropy—are consistent with 
previous examinations of peptide–SH3 binding (see Table S1 
for thermodynamic data).39 Moving the location of the rhodium 
center toward the N-terminus, away from the histidine, led to a 
drop in binding affinity. The N13DRh metallopeptide, a 
convenient negative control with the rhodium ceneter too far 
for histidine interactions, binds with micromolar activity, 
similar to simple SH3 binding of the parent peptide. We 
concludethat the vast affinity improvement is due to rhodium 
coordination to unique histidine residue(s). The Hck domain— 
which shares one of two key histidine residues (Lyn His78; Hck 
His93) with Lyn—also exhibited significant affinity (Kd 26 nM, 
Table 1, entry 2) for the S2ERh metallopeptide. A 
metallopeptide N13DRh, which positions the rhodium center far 
away from the Lyn His78 and His96 provided no affinity 
enhancement relative to the parent peptide. 
 
Figure 2. (a) Structure of the optimal Lyn-binding peptide, S2ERh. (b,c) ITC analysis 
for affinity determination of S2ERh (b) and a negative control (c).  
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 The remarkable 6-nM affinity, far stronger than that of any 
reported non-protein ligand for SH3 domains, led us to study 
the structural basis of the observed affinity. Mutation 
experiments prove that both His78 and His96, in the Lyn SH3 
binding pocket, contribute to potent binding. The H78A and 
H96A mutants bind to S2ERh with 20- and 39-nM affinity, 
respectively. The H78A and H96A double mutant binds much 
more weakly (>5 µM). These results indicate that both histidine 
residues bind to the dirhodium core, presumably by binding in a 
co-linear fashion to each of the two rhodium atoms. The two 
single-histidine mutants bind with roughly similar affinity, 3–7 
fold less potent than the native Lyn, and ~100x more potent 
than the parent peptide, implying that both histidines are well 
positioned to coordinate to the dirhodium center. That the 
majority of the stabilization energy comes from the first 
histidine coordination is consistent with the negative 
cooperativity generally seen for axial coordination to 
rhodium(II): a second coordination in solution is roughly two 
orders of magnitude less favorable.40-43 
Table 1. Affinity (Kd) of selected metallopeptides for various human SH3 
domains.a 
  SH3 Kd (nM) 





1 Lyn 6.1 30 152 1,203    
2 Hck 26 b 52 b 51 544 2315   
3 Lck 481  3788 239 79   
4 Yes 610 3,745  301    
5 Fyn 769 5,130  238    
6 Src 327       
7 Abl 5747   8,850  22 7,194 
a All affinities measured by ITC. b ITC measurements with Hck contain a 
second low-affinity (>20 µM) feature, presumably due to non-specific 
histidine interactions. Abl-binding peptide (P40) = "p40": APTYSPPPPP. 
P40-A1ERh = ERhPTYSPPPPP. P40-Y4ERh = APTERhSPPPPP. Fyn binding 
data was previously reported (ref. 52). 
 The structure of the Lyn SH3 domain strongly suggests that 
two histidine residues are well positioned to coordinate to a 
dirhodium core, with the histidine side chains approaching from 
different directions and coordinating separate rhodium atoms. 
This bidentate trans coordination mode—reminiscent of 
metalloproteins such as cytochrome C.44—is rare in small 
molecule ligands. We conducted a computational study using a 
combination of molecular mechanics and quantum mechanics 
to faithfully describe protein folding as well as rhodium 
coordination. Specifically, previously determined structures of 
Lyn (PDB ID: 1W1F) and Rh2(OAc)4
45 were used as a starting 
model for the metalloprotein. Four structural isomers based on 
coordination of rhodium with His78 and His96 γ- and δ-
nitrogen atoms were constructed. Geometry minimization was 
carried out on the four initial structures using the UFF force 
field in which the structural environment of Rh2(OAc)4 and the 
respective Rh-His bonds were frozen.46 The Glu carboxylate 
side chain of S2E replaced an equatorial acetate ligand in order 
to position the peptide near the SH3 binding groove. Two-layer 
ONIOM calculations were performed on Lyn-S2ERh isomers 
using the DFT functional B3LYP for the QM layer and the 
force field UFF for the MM layer. The most energetically stable 
isomer is predicted to arise from bis-histidine binding through 
both γ-nitrogen atoms.47 This binding motif also necessitates 
the least displacement of the native Lyn structure (Figure S13). 
In the optimized structure of the Nγ-Nγ isomer (Figure 3a), the 
metallopeptide (yellow) overlays closely with a published 
structure for an SH3-binding peptide (magenta) in the C-
terminal region. At the extreme N-terminus, on the other hand, 
the peptide backbone is displaced, and the short helical 
structure of the canonical peptide structure is replaced by the 
dirhodium core occupying the cleft between the two histidine 
residues (Figure 3b). A slice depicting the histidine-containing 
region of the reported Lyn SH3 structure (Figure 3c, yellow) 
and the calculated Lyn structure bound to S2ERh (green), 
demonstrates what little backbone alterations are needed to 
accommodate bis-histidine binding to the rhodium core. Based 
on the model, only small conformational changes in the Glu95-
Trp99 and Ile77-Asp80 loops are required to position His78 
and His96 to interact with the dirhodium tetraacetate, consistent 
with the small entropic penalty for binding observed in the ITC 
measurements.   
 
Figure 3.  Computational models of S2E
Rh
 bound to Lyn SH3. a) QM/MM-
optimized structure of N-Nisomer of Lyn-S2E
Rh
 with overlayed native SH3-
binding peptide ligand (magenta). b) Depiction of the histidine flanked cleft of 
LYN where dirhodium binding occurs. c) Top slice view of an overlay of native 
LYN SH3 (yellow) and the N-Nisomer of Lyn-S2E
Rh 
(green).  d) Overview of the 
QM/MM optimization. High layer (DFT): tube. Low layer (MM): stick. See text 
and ESI for details. 
 Rhodium(II) conjugation represents a general way to build 
potent SH3 ligands in a predictable way from structural 
information and simple design principles. Through a 
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combination of sequence optimization and judicious choice of 
rhodium location, it is possible to alter specificity to favor other 
SH3 domains. Lck is another Src-family protein, with high 
similarity to Lyn and possessing similarly SH3-binding-peptide 
preferences.48 However, Lck lacks the Lyn His96 residue 
(Figure 1), and does not bind tightly to S2ERh (Figure 2). On the 
other hand, Lck has a unique histidine (His70, see Figure 1b) 
residue at the bottom of the pocket. By moving the rhodium 
core to the 12th residue (P12DRh), the affinity for Lck increased 
to 79 nM as a consequence of specific interactions with the 
unique His70 residue (Figure 2). Similarly, selective affinity for 
a third Src-family member, Hck, could be achieved with the 
R6ERh peptide (Table 1, entry 2), presumably due to 
interactions with the unique His94 (homologous to Lyn 79) 
found in Hck. The clean formation of 1:1 
protein/metallopeptide complexes, even in the presence of 
excess metallopeptide was also indicated by analytical FPLC 
(see ESI). 
 An even more dramatic effect was observed with the Abl, a 
kinase outside of the Src family. The Abl kinase, and its 
constitutively active mutant variants, play key roles in tumor 
growth, and Abl is an important protein in cancer biology and a 
therapeutic target.8,49,50 Potent ligands for the Abl SH3 likewise 
represent an unmet need. Despite strong homology, Abl has a 
different peptide sequence preference than the Src-family 
kinases; it generally exhibits >5-µM affinity for peptides that 
interact with Src-family SH3 domains (Figure 2). Abl binds the 
peptide p40 with 0.40-µM affinity.51 Abl also has a unique and 
accessible His95 residue (homologous to Lyn 95, Figure 1). We 
designed two rhodium-containing variants of the Abl-binding 
peptide, p40-A1ERh and p40-Y4ERh. While p40-Y4ERh did not 
improve binding, the p40-A1Rh peptide, which modeling studies 
suggested is better designed to position the rhodium core near 
the key His95 residue, binds Abl with 22-nM affinity, similar to 
our best Src-family ligands (Table 1). As with Lyn, the p40-
A1Rh peptide represents the most potent ligand for the Abl SH3 
domain yet reported.  
 
Figure 4. ITC analysis of Abl SH3 binding to designed metallopeptides.  
 We used catalytic protein modification to examine the 
potency of the metallopeptide–Lyn interaction in a cell-like 
environment. We have previously shown that rhodium 
metallopeptides catalyze protein modification in lysate, with 
specificity provided by molecular recognition.52 More recent 
work has demonstrated that SH3 domains are amenable to this 
approach, permitting site-specific alkyne functionalization of 
specific SH3 domains in lysate.53 For example, in the presence 
of R5ERh metallopeptide and an alkyne–diazo reagent, the Yes 
SH3 domain (expressed as a fusion with maltose-binding 
protein, MBP) is readily tagged with an alkyne group, and the 
modification visualized by alkyne-azide cycloaddition on a blot 
membrane (Figure 5, left box).53 Because catalytic covalent 
modification requires metallopeptide (R5ERh) binding to the 
Yes SH3 domain, the addition of an exogenous high-affinity 
domain (Lyn, Kd = 81 nM) would be predicted to out-compete 
metallopeptide binding to the substrate (Yes, Kd = 1,740 nM) 
and thus to prevent modification. Indeed, when these reactions 
are dosed with Lyn SH3, a drastic drop in labelling is observed, 
consistent with Lyn effectively outcompeting Yes and all other 
cellular proteins for the metallopeptide. Lyn itself is not 
modified by the catalyst, consistent with a Lyn–metallopeptide 
binding model (Figure 3b) in which both rhodium coordination 
sites are blocked by histidine residues.  
 
Figure 5. Potent sequestration of a metallopeptide catalyst by Lyn SH3. (left box) 
In the absence of Lyn, a metallopeptide (R5ERh) catalyzes covalent attachment of 
an alkyne-containing small molecule to the Yes SH3 domain (expressed as a 
fusion with MBP) in cell lysate, visualized after reaction with a fluorogenic 
azide.53 The activity of the rhodium metallopeptide catalyst is inhibited by added 
Lyn SH3, indicating selective binding in lysate. (right box) Total protein (Ponceau) 
stain of the lysate reactions. Conditions: MBP-Yes fusion (2 µM), metallopeptide 
(10 µM), and MBP-Yes fusion (2 µM) in E. coli lysate, diluted 2× with tert-
butylhydroxylamine buffer at pH 6.2 at 4 °C.  
 The potent Lyn SH3 binder we developed has functional 
consequences for Lyn kinase. The SH3 domain plays many 
regulatory and specificity roles for the Src family kinases in 
vivo. In full-length kinase, the SH3 domain is bound to a 
portion of the catalytic kinase domain, which abrogates kinase 
activity. The functional consequence of ligand binding to the 
SH3 domain is release of the SH3 domain from the kinase 
domain and subsequent full activation of kinase activity. 
Previous work indicates that SH3 interactions are necessary and 
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sufficient for complete kinase activation, while SH2 
interactions have a smaller effect.5 
 We examined phosphorylation of a peptide substrate at low 
enzyme concentration (0.074 µM) and short reaction time (t = 5 
min) to minimize the alternative autophosphorylation activation 
pathway (Figure 6). Kinase activation with traditional ligands 
has typically required high ligand concentrations (~1 mM) to 
overcome the intramolecular nature of the SH3–kinase domain 
interaction. Consistent with previous results, the parent peptide, 
S2E, showed slight activation only above 100 µM. Simple 
rhodium complexes (Rh2(OAc)4 displayed no activation (blue 
circle). However, the S2ERh metallopeptide exhibited strong 
Lyn activation at 200 nM, roughly three orders of magnitude 
lower than the parent peptide. Complete activation response 
was achieved at 630 nM. The only known SH3 ligand that 
exhibits comparable levels of activation within the Src family is 
the full-length HIV Nef protein, which binds tightly to Hck 
kinase. Taken together, the kinase activation and lysate-based 
inhibition demonstrate activation of the kinase target and 
activity in cell-like environments, and they provide  
confirmation of the potency gains made possible by rhodium 
conjugates. 
 
Figure 6. Activation of Lyn kinase activity by a metallopeptide, S2ERh, and the 
parent peptide, S2E. The negative control, Rh2(OAc)4, had no effect on kinase 
activity. Full-length Lyn kinase (74 nM) was treated with substrate peptide and 
ATP. Kinase activity was measured after 5 min in an adaptation of reported 
methods.
5
 See ESI for details. 
Conclusions 
 The S2ERh metallopeptide is the first ligand with single-
digit nanomolar affinity yet reported for Lyn SH3 and is among 
the very few highly potent SH3 ligands yet reported. In 
addition, the S2ERh metallopeptide is the first reported small 
molecule that exhibits functional activation of Lyn kinase 
activity under biologically relevant concentrations. Importantly, 
an approach based on metallopeptides allows both structure-
guided inhibitor design and selective inhibition within 
homologous protein families that are difficult to differentiate 
with traditional inhibitors. By targeting unique residues at the 
periphery of the binding pocket, we are able to design 
specificity for Lyn, and, separately, for Lck and Hck, despite 
the large sequence homology of Src-family SH3 domains. A 
nanomolar Abl ligand demonstrates that the approach can be 
generalized to SH3 types beyond the Src family. Rhodium-
containing inhibitors thus should serve as powerful tools to 
probe homologous protein families. 
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